TGF-beta plays a critical role in liver fibrosis, with both profibrogenic and anti-inflammatory effects. It is involved in the transdifferentiation of hepatic stellate cells (HSC) into myofibroblasts, and regulates cell proliferation and apoptosis. TGF-beta is primarily secreted as an inactive complex, and its activation involves proteolytic processing. The TGF-beta signaling pathway is complex, with crosstalk between different pathways influencing its effects. TGF-beta is a key player in liver disease, including fibrosis and inflammation, and its measurement in blood may serve as a diagnostic tool. Antifibrotic strategies aim to inhibit TGF-beta function or synthesis. TGF-beta signaling in liver cells involves receptor activation, Smad-mediated signaling, and interactions with other pathways. TGF-beta is a potent suppressor of hepatocyte proliferation and inducer of apoptosis. It is also involved in the activation of HSC, leading to fibrogenesis. TGF-beta signaling is regulated by various factors, including Smad proteins, and its dysregulation contributes to liver diseases. TGF-beta is involved in the activation of HSC, leading to fibrogenesis, and its inhibition may be a therapeutic target. TGF-beta also plays a role in parenchymal cell apoptosis, and its dysregulation may contribute to liver diseases. TGF-beta is a potential diagnostic marker in liver disease, and its levels may be used to assess liver function and disease progression. Therapeutic approaches to inhibit TGF-beta include the use of antagonists, antioxidants, and gene therapy. These approaches aim to reduce fibrosis and improve liver function. TGF-beta is a key factor in liver fibrosis and its regulation is essential for maintaining liver homeostasis. The role of TGF-beta in liver disease is complex, and further research is needed to develop effective therapeutic strategies.TGF-beta plays a critical role in liver fibrosis, with both profibrogenic and anti-inflammatory effects. It is involved in the transdifferentiation of hepatic stellate cells (HSC) into myofibroblasts, and regulates cell proliferation and apoptosis. TGF-beta is primarily secreted as an inactive complex, and its activation involves proteolytic processing. The TGF-beta signaling pathway is complex, with crosstalk between different pathways influencing its effects. TGF-beta is a key player in liver disease, including fibrosis and inflammation, and its measurement in blood may serve as a diagnostic tool. Antifibrotic strategies aim to inhibit TGF-beta function or synthesis. TGF-beta signaling in liver cells involves receptor activation, Smad-mediated signaling, and interactions with other pathways. TGF-beta is a potent suppressor of hepatocyte proliferation and inducer of apoptosis. It is also involved in the activation of HSC, leading to fibrogenesis. TGF-beta signaling is regulated by various factors, including Smad proteins, and its dysregulation contributes to liver diseases. TGF-beta is involved in the activation of HSC, leading to fibrogenesis, and its inhibition may be a therapeutic target. TGF-beta also plays a role in parenchymal cell apoptosis, and its dysregulation may contribute to liver diseases. TGF-beta is a potential diagnostic marker in liver disease, and its levels may be used to assess liver function and disease progression. Therapeutic approaches to inhibit TGF-beta include the use of antagonists, antioxidants, and gene therapy. These approaches aim to reduce fibrosis and improve liver function. TGF-beta is a key factor in liver fibrosis and its regulation is essential for maintaining liver homeostasis. The role of TGF-beta in liver disease is complex, and further research is needed to develop effective therapeutic strategies.